AsclepiX Therapeutics Employee Directory
Biotechnology ResearchMaryland, United States2-10 Employees
AsclepiX Therapeutics is a clinical-stage biotechnology company focused on developing peptide-based therapies for retinal diseases. It leverages computational biology from Johns Hopkins to identify peptide regulators of vascular and cellular homeostasis, guiding the development of candidates for retinal conditions. The lead candidate, AXT107, inhibits pro-angiogenic VEGFR2 signaling and activates the vessel-stabilizing Tie2 receptor. Based in Baltimore, Maryland, the company operates within the biotechnology sector's ophthalmology and vascular biology niche, aiming to address vision-threatening retinal vascular diseases. Its work targets patients whose retinal conditions involve abnormal blood vessel growth and vascular instability, seeking therapies that modulate these pathways.